Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10142335 | 0.89 | RECQL (0.67) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL20368911 | 0.85 | CYP3A4 (0.70) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL28246238 | 0.85 | CYP3A4 (0.74) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL5709879 | 0.84 | CYP3A4 (0.64) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL5420738 | 0.84 | CYP3A4 (0.68) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL5420740 | 0.84 | CYP3A4 (0.68) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL22091828 | 0.84 | CYP3A4 (0.68) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL19611353 | 0.83 | CYP3A4 (0.66) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL22091930 | 0.83 | CYP3A4 (0.66) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL21811427 | 0.83 | CYP3A4 (0.66) | CYP3A4TSHRTDP1ATMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3598999-A1 | METHOD FOR ENRICHING KARANJA OIL | Biosynthis (FR) | 2020-01-29 | — | — | EP | disclosed |
| US-20160160142-A1 | QUATERNARY AMMONIUM COMPOUNDS AS FUEL OR LUBRICANT ADDITIVES | INNOSPEC LIMITED (GB) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160160142-A1 | QUATERNARY AMMONIUM COMPOUNDS AS FUEL OR LUBRICANT ADDITIVES | KAT2B, KAT6A, KAT5 | CYP3A4 1469/4885TSHR 2388/4885TDP1 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.